Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Income towards Parent Company of -$13.1 million in Q1 2026, down 12.73% quarter-over-quarter from -$11.6 million in Q4 2025, and down 183.23% on a YoY basis from $15.7 million in Q1 2025.
Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 183.23% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$42.2 million (down 12.62% YoY), while the FY2025 annual figure was -$13.3 million, up 77.45% from the prior year.
- Income towards Parent Company was -$13.1 million for Q1 2026 at Corvus Pharmaceuticals, down from -$11.6 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $15.7 million in Q1 2025 to a low of -$39.5 million in Q3 2024.
- Historically, Income towards Parent Company has averaged -$8.2 million across 5 years, with a median of -$7.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company plunged 669.91% in 2024, then surged 364.98% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$5.7 million in 2022, then advanced by 7.36% to -$5.2 million in 2023, then sank by 89.35% to -$9.9 million in 2024, then retreated by 16.85% to -$11.6 million in 2025, then fell by 12.73% to -$13.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$13.1 million (Q1 2026), -$11.6 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.61 Mn |
| Sep 30, 2025 | -9.83 Mn |
| Jun 30, 2025 | -7.61 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -39.54 Mn |
| Jun 30, 2024 | -3.69 Mn |
| Mar 31, 2024 | -5.94 Mn |
| Dec 31, 2023 | -5.25 Mn |
| Sep 30, 2023 | -5.14 Mn |
| Jun 30, 2023 | -5.22 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -12.47 Mn |
| Jun 30, 2022 | -7.01 Mn |
| Mar 31, 2022 | -7.41 Mn |
| Dec 31, 2021 | -6.81 Mn |
| Sep 30, 2021 | -9.05 Mn |
| Jun 30, 2021 | -11.29 Mn |